Stock Events

Stock Events

Angion Biomedica 

$1
16
-$97-98.98% Thursday 20:00

Statistics

Day High
-
Day Low
-
52W High
-
52W Low
-
Volume
-
Avg. Volume
-
Mkt Cap
30.11M
P/E Ratio
0
Dividend Yield
-
Dividend
-

Earnings

14AugExpected
Q4 2021
Q1 2022
Q2 2022
Q3 2022
Q4 2022
Q1 2023
Q2 2023
-0.62
-0.22
0.18
0.58
Expected EPS
-0.57
Actual EPS
N/A

Financials

-1,966.41%Profit Margin
Unprofitable
2013
2018
2019
2020
2021
2022
2.3MRevenue
-45.25MNet Income

Analyst Ratings

18Average Price Target
The highest estimate is 20.00.
From 3 ratings within the last 6 months. This is not an investment recommendation.
Buy
100%
Hold
0%
Sell
0%

People Also Follow

This list is based on the watchlists of people on Stock Events who follow ANGN. It's not an investment recommendation.
Alphabet
79493
GOOGL
Apple
69146
AAPL
Microsoft
64576
MSFT
Amazon
60260
AMZN

Competitors

This list is an analysis based on recent market events. It's not an investment recommendation.
Moderna
MRNA
Mkt Cap21.3B
Moderna Inc. focuses on mRNA-based therapies, including cancer vaccines, directly competing with Elicio's amphiphile technology in cancer immunotherapy.
BioNTech
BNTX
Mkt Cap26.03B
BioNTech SE develops targeted cancer therapies using mRNA, similar to Elicio's approach in stimulating robust immune responses against cancer.
Novavax
NVAX
Mkt Cap1.44B
Novavax, Inc. is involved in the development of vaccines, including for cancer, which competes with Elicio's cancer vaccine platforms.
Gilead Sciences
GILD
Mkt Cap170.84B
Gilead Sciences, Inc. has a strong portfolio in oncology and cell therapy, areas where Elicio is also trying to make an impact.
AMGEN
AMGN
Mkt Cap191.53B
Amgen Inc. works on innovative therapeutics in oncology, including immune-oncology, a field where Elicio is also active.
Bristol-Myers Squibb
BMY
Mkt Cap122.85B
Bristol-Myers Squibb Company offers immunotherapy treatments for cancer, competing with Elicio's cancer immunotherapies.
Merck
MRK
Mkt Cap294.39B
Merck & Co., Inc. is a leader in cancer immunotherapy with products like Keytruda, competing in the same space as Elicio's therapies.
Pfizer
PFE
Mkt Cap156.77B
Pfizer Inc. develops and markets drugs and vaccines, including cancer treatments, which overlaps with Elicio's therapeutic areas.
Regeneron Pharmaceuticals
REGN
Mkt Cap79.35B
Regeneron Pharmaceuticals, Inc. is known for its innovative biopharmaceuticals targeting various diseases, including cancer, similar to Elicio's focus.
Novartis
NVS
Mkt Cap293.34B
Novartis AG has a broad focus in healthcare, including advanced therapies in oncology, competing with Elicio's cancer treatment technologies.

About

Angion Biomedica Corp., a biopharmaceutical company, focuses on the discovery, development, and commercialization of small molecule therapeutics for acute organ injuries and fibrotic diseases. The company's lead product candidate is ANG-3070, an oral tyrosine kinase receptor inhibitor in development as a treatment for fibrotic diseases, primarily in the kidney and lung. It also develops ANG-3777, a hepatocyte growth factor mimetic to treat acute organ injuries, such as delayed graft function; ROCK2 inhibitors programs for fibrotic diseases; and CYP11B2 inhibitor program. The company was incorporated in 1998 and is based in Uniondale, New York.
Show more...
CEO
Employees
37
Country
United States
ISIN
US03476J1079
WKN
000A2QNWT

Listings

MU
DE
9HA.MU
STU
DE
9HA.STU
F
DE
9HA.F
XNAS
US
ELTX

0 Comments

Share your thoughts

FAQ

What is Angion Biomedica stock price today?▼
The current price of ANGN is $1 USD — it has decreased by -98.98% in the past 24 hours. Watch Angion Biomedica stock price performance more closely on the chart.
What is Angion Biomedica stock ticker?▼
Depending on the exchange, the stock ticker may vary. For instance, on exchange Angion Biomedica stocks are traded under the ticker ANGN.
What is Angion Biomedica market cap?▼
Today Angion Biomedica has the market capitalization of 30.11M
What is Angion Biomedica revenue for the last year?▼
Angion Biomedica revenue for the last year amounts to 2.3M USD.
What is Angion Biomedica net income for the last year?▼
ANGN net income for the last year is -45.25M USD.
How many employees does Angion Biomedica have?▼
As of April 23, 2026, the company has 37 employees.
In which sector is Angion Biomedica located?▼
Angion Biomedica operates in the Manufacturing sector.
When did Angion Biomedica complete a stock split?▼
The last stock split for Angion Biomedica was on June 02, 2023 with a ratio of 1:10.